FILE PHOTO: The Eli Lilly and Company’s logo is displayed during a press conference in Houston, Texas, U.S., September 23, 2025. REUTERS/Antranik Tavitian/File Photo

(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.

Here are some reactions to Lilly joining the trillion dollar club:

MARK PRESKETT, SENIOR PORTFOLIO MANAGER AT MORNINGSTAR WEALTH

"The cloud that has been casting a shadow over the healthcare industry is slowly lifting. The Eli Lilly agreement, along with the Trump deal with Pfizer last month, is providing investors with much needed clarity around drug pricing. We would expect further deals with key pharmaceutical firms to be announced in the coming months, and see the rally as having ample room to continue. We continue to see momentum building and believe that healthcare is the cheapest sector from a long-term perspective."

GEOFF MEACHAM, ANALYST AT CITI

"I think the market cap / liquidity / positioning of being a mega cap healthcare company positions Lilly well as a viable alternative to the "Mag7". With the recent tech sell off and also going into 2026, I think investors are re-evaluating their allocations towards tech (TMT broadly) and since healthcare has underperformed most of this year, it's a viable option. Within that Lilly's fundamentals stand out – among the fastest growers on revenue/EPS."

EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS

"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."

HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST

"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."

(Reporting by Mariam Sunny, Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)